Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Form 6-K submitted on February 4, 2020, reporting the consolidated financial results for the nine-month period ended December 31, 2019 (April 1 to December 31, 2019). The results are presented under International Financial Reporting Standards (IFRS). The period includes the full impact of the Shire acquisition, which closed on January 8, 2019, and reflects retrospective adjustments to the purchase price allocation finalized during this period.
Key Financial Metrics
| Metric | 9 Months Ended Dec 31, 2019 | 9 Months Ended Dec 31, 2018 | Change (%) |
|---|---|---|---|
| Revenue | 2,519,486 Million JPY | 1,380,013 Million JPY | +82.6% |
| Operating Profit | 162,544 Million JPY | 284,420 Million JPY | -42.9% |
| Profit Before Tax | 56,008 Million JPY | 208,379 Million JPY | -73.1% |
| Net Profit (Period) | 42,728 Million JPY | 164,353 Million JPY | -74.0% |
| Net Profit (Attributable to Owners) | 42,517 Million JPY | 164,434 Million JPY | -74.1% |
| Basic EPS | 27.31 JPY | 209.87 JPY | -87.0% |
| Core Operating Profit | 792.2 Billion JPY | 344.6 Billion JPY | +129.9% |
| Underlying Core EPS | 359.37 JPY | n/a | - |
| Total Assets | 13,031,494 Million JPY | 13,792,773 Million JPY (Mar 31, 2019) | -5.5% |
| Total Equity | 4,876,219 Million JPY | 5,185,991 Million JPY (Mar 31, 2019) | -6.0% |
| Net Cash from Operating Activities | 484,315 Million JPY | 210,996 Million JPY | +129.5% |
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 82.6% primarily due to the inclusion of Shire products (1,155.5 billion JPY). On an underlying basis (constant currency, excluding divestitures), revenue declined 1.2% due to generic erosion and competitive pressure, offset by growth in 14 global brands (+20.4%).
- Profit Decline: Reported operating profit and net profit decreased significantly (42.9% and 74.0% respectively). This was driven by high amortization and impairment charges (329.1 billion JPY) related to Shire intangible assets, increased R&D expenses, and restructuring costs.
- Core Performance: Despite reported losses, Core Operating Profit (excluding non-cash amortization and integration costs) increased 129.9% to 792.2 billion JPY, with an underlying margin of 30.9%.
- Balance Sheet: Total assets decreased due to amortization of intangibles, foreign exchange impacts, and the divestiture of XIIDRA. Bonds and loans decreased by 529.2 billion JPY due to redemptions and repayments.
- Cash Flow: Operating cash flow improved significantly to 484.3 billion JPY, driven by non-cash adjustments (depreciation/amortization) and inventory management, despite lower net profit.
Guidance, Outlook, and Risks
- Revised FY2019 Forecast: Management revised the full-year forecast upward.
- Revenue: Increased to 3,286.0 billion JPY (from 3,260.0 billion JPY).
- Operating Profit: Revised to a profit of 10.0 billion JPY (from a loss of 110.0 billion JPY), largely due to finalized purchase price allocation adjustments reducing amortization and cost of sales.
- Net Profit: Revised to a loss of 162.0 billion JPY (from a loss of 273.0 billion JPY).
- Core Operating Profit: Increased to 950.0 billion JPY.
- Underlying Guidance: Underlying Revenue Growth remains "Flat to slightly increasing." Underlying Core Operating Profit Margin is expected in the "High-twenties %." Underlying Core EPS guidance was raised to 385-405 JPY (from 370-390 JPY).
- Dividends: Projected annual dividend remains 180 JPY per share.
- Risks and Contingencies:
- Legal: Takeda settled patent infringement lawsuits with Roche regarding ENTYVIO in Europe; payment obligations are not expected to be material.
- Product Issues: NATPARA was recalled in the U.S. in September 2019 due to a rubber septum issue, impacting Rare Metabolic sales.
- Integration: Ongoing integration of Shire continues to incur restructuring and transaction costs.
Key Facts for Investor Verification
- Purchase Price Allocation: Verify the impact of the finalized Shire purchase price allocation, which reduced amortization and cost of sales by 118.8 billion JPY compared to the previous forecast, significantly altering the reported profit outlook.
- Underlying vs. Reported: Distinguish between reported results (heavily impacted by non-cash amortization) and underlying/core metrics, which show positive operational momentum.
- Debt Reduction: Confirm the reduction in net debt through bond redemptions (approx. 500 billion JPY in USD notes) and the new 700 billion JPY commitment facility.
- Product Performance: Monitor the performance of key Shire assets (e.g., TAKHZYRO, VYVANSE) versus legacy Takeda products facing generic erosion (e.g., VELCADE, LIALDA).
- FX Sensitivity: Note that underlying growth is calculated on a constant currency basis; actual reported results remain sensitive to JPY/USD and JPY/EUR fluctuations.